Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
christensenella minuta SJ-2
- Development stage
- Preclinical
- Lead developer
- YSOPIA Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Christensenella minuta SJ-2 is a specific strain of the anaerobic, Gram-negative bacterium Christensenella minuta, which belongs to the family Christensenellaceae. This species is recognized as a keystone member of the human gut microbiome and has been associated with beneficial metabolic effects. Supplementation with C. minuta has demonstrated preventive and remedial benefits in preclinical models by modulating gut microbiota composition, reducing body weight gain, improving glycemic control, lowering plasma leptin levels, and alleviating acetaminophen-induced liver injury through its impact on host metabolism and energy homeostasis[1][3][4]. The mechanisms are thought to involve modulation of microbial community structure and enhancement of energy loss via increased stool biomass[4]. The strain designation "SJ-2" refers to a particular isolate but detailed information about this specific strain's unique properties or clinical development status is limited in public sources.
- Other names
- christensenella minutaC. minuta SJ-2
02
Targets
GM (Gut microbial community composition)
Beyond the preview
Go deeper on christensenella minuta SJ-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on christensenella minuta SJ-2.